Global CAR T Cell Therapy Market to 2026 - by Regions, Targeted Antigens, Clinical Trials/Study & Companies -

DUBLIN--()--The "CAR T Cell Therapy Market Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies" report has been added to's offering.

This latest study report CAR T Cell Therapy Market Global Forecast by Regions (North America, Europe, Asia Pacific, Latin America, Middle East, Africa), Targeted Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvII, Others), Clinical Trials/Study (CD19, CD20, GD2, CD22, CD30, CD33, HER1, HER2, MESO, EGFRvII), Companies (Novartis, Gilead Sciences (Kite Pharma), Celgene Corporation (Juno Therapeutics), Celyad) provides a detailed and comprehensive insight of the global CAR T cell therapy market.

For many years, the support of cancer therapy was chemotherapy, surgery and radiation therapy. However, in recent times, CAR-T cell therapy has been introduced as an incredibly supportive treatment for cancer patients. Since the introduction of chemotherapy, this treatment is one of the most significant breakthroughs. In this therapy, immune cells are collected from patients, and it is modified in the laboratory by doctors. After modification, these immune cells are infused back into the patient as they can easily recognize and kill cancer cells. These infused cells get multiplied and stay in the body as living drugs. According to analysis, CAR-T Cell Therapy Market is expected to be USD 7.4 Billion by the end of the year 2028.

Growth Factors for CAR-T Cell Therapy

Factors such as growing numbers of cancer in adults and children, and increasing policy initiatives to encourage cell therapy research in cancer, and increasing numbers of clinical trials worldwide are some of the main drivers for the global demand for CAR T cell therapy. The economic scenario in the CAR-T cell therapy industry is very dynamic, and key players compete with each other to gain access to major markets in the United States and Europe. Companies are seeking to secure treatment facilities to increase access for patients to their treatments.

Developments did by Companies in CAR T Cell Therapy

In 2017, a new milestone was set for oncology patients when the FDA approved the first two CD19-targeted known as (Chimeric Antigen Receptor) CAR T cell therapies produced by Novartis and Gilead Sciences known as Kite Pharma in the United States. Such two approvals have helped to improve the global demand for CAR T cell therapy because more companies are searching for this excellent opportunity to reach the marketplace. More than 200 CAR T clinical trials are ongoing or completed in various parts of the world. In 2018, Novartis announced its 33 approved centres in the U.S. and Gilead announced its 28 approved centres for the care of patients. Companies are also coming up with new developments in the field.

Key Topics Covered:

1. Executive Summary

2. Global Chimeric Antigen Receptor (CAR)-T cell Therapy Market

3. Market Share - CAR-T Cell Therapy

3.1 By Geographical Region

3.2 By Targeted Antigens

4. Targeted Antigen Market

4.1 CD19

4.1.1 Introduction

4.1.2 Market Size and Forecast

4.2 CD20

4.3 GD2

4.4 CD22

4.5 CD30

4.6 CD33

4.7 HER2

4.8 Mesothelin (MESO)


4.10 Others

5. Geographical CAR-T Cell Therapy Market (2016 -2026)

5.1 North America

5.2 Europe

5.3 Asia Pacific

5.4 Latin America

5.5 Middle East

5.6 Africa

6. Global - CAR-T Cell Clinical Trials/Study

6.1 CD19

6.2 CD20

6.3 CD22

6.4 CD30

6.5 CD33


6.7 GD2

6.8 HER1

6.9 HER2

6.10 MESO

7. China CAR-T Cells Clinical Trials Details

7.1 By Cities CAR-T Cells Clinical Trials

7.2 CD19 Directed CAR-T Cells Clinical Trials

7.3 Non-CD19 Directed CAR-T Cells Clinical Trials

7.4 Solid Tumors CAR-T Cells Clinical Trials

8. CAR-T Cell Therapy SWOT Analysis

8.1 Strength

8.2 Weakness

8.3 Opportunities

8.4 Threats

9. Regulation in CAR-T Cell Therapy

9.1 United States

9.2 European Union

9.3 China

10. IPO/Investment/Funding/Partnership in CAR-T Cell Therapy Market

10.1 Venture Capital Investment

10.2 Initial Public Offerings of CAR-T Companies

10.3 CAR-T Companies Strategic Partnerships/Deals

10.4 Key CAR-T Technology Deals

11. Growth Drivers

11.1 FDA Approvals of CAR-T Therapy

11.2 Dramatically Increasing Number of CAR-T Cell Trials Globally

12. Challenges

12.1 Regulatory Challenges

12.2 Very Expensive CAR-T Therapy Treatment

13. Novartis

13.1 Company Overview

13.2 Initiatives

13.2.1 Point 1

13.2.2 Point 2 Kymriah (tisagenlecleucel), First-in-class CAR-T Therapy from Novartis Received Second FDA Approval

13.2.3 Point 2

13.3 Financial Insight

14. Gilead Sciences (Kite Pharma)

14.1 Company Overview

14.2 Company Initiatives

14.2.1 Point 1

14.2.2 Point 2

14.3 Company Financial Insight

15. Celgene Corporation (Juno Therapeutics)

15.1 Company Overview

15.2 Company Initiatives

15.2.1 Point 1

15.2.2 Point 2

15.3 Company Financial Insight

16. Celyad

16.1 Company Overview

16.2 Company Initiatives

16.2.1 Point 1

16.2.2 Point 2

16.2.3 Point 3

16.3 Financial Insight

Companies Mentioned

  • Novartis
  • Gilead Sciences (Kite Pharma)
  • Celgene Corporation (Juno Therapeutics)
  • Celyad

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900